Curis (CRIS) to Release Quarterly Earnings on Monday

Curis (NASDAQ:CRIS) is expected to be issuing its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.4360) per share and revenue of $3.2490 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 19, 2026 at 4:30 PM ET.

Curis (NASDAQ:CRIS) last posted its quarterly earnings data on Thursday, March 19th. The biotechnology company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The business had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $3.25 million. On average, analysts expect Curis to post $-7 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Curis Stock Up 1.9%

Shares of NASDAQ:CRIS opened at $0.77 on Monday. The company’s fifty day moving average is $0.98 and its two-hundred day moving average is $1.24. The company has a market cap of $10.59 million, a P/E ratio of -0.65 and a beta of 3.02. Curis has a 12-month low of $0.75 and a 12-month high of $3.13.

Institutional Investors Weigh In On Curis

A number of institutional investors have recently modified their holdings of CRIS. Jane Street Group LLC increased its stake in shares of Curis by 71.8% in the fourth quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 10,586 shares during the last quarter. XTX Topco Ltd acquired a new stake in Curis during the fourth quarter valued at $26,000. Squarepoint Ops LLC boosted its position in Curis by 46.2% during the fourth quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 27,343 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in Curis by 2,883,237.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock valued at $228,000 after purchasing an additional 230,659 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in Curis by 37.3% in the fourth quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock valued at $238,000 after purchasing an additional 65,404 shares in the last quarter. Institutional investors and hedge funds own 29.97% of the company’s stock.

Curis News Summary

Here are the key news stories impacting Curis this week:

• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating with a $17.00 price target — a highly bullish analyst endorsement that can attract speculative buying given the large upside to the current price. Benzinga
• Positive Sentiment: Company and management continue to advance oncology programs: Curis is targeting full enrollment in its PCNSL registrational study within 12–18 months and is progressing a CLL proof‑of‑concept — milestones that would materially de‑risk and re‑rate the pipeline if achieved. Seeking Alpha
• Neutral Sentiment: Curis issued a fourth-quarter 2025 business update and hosted a conference call — useful for detail and guidance but neutral until management gives clear forward guidance or cash/runway updates. PR Newswire
• Neutral Sentiment: Multiple transcripts of the Q4 2025 earnings call are available (MSN/Yahoo/Seeking Alpha) for investors who want management color; transcripts themselves don’t change fundamentals but help interpret pipeline timelines. MSN Transcript
• Negative Sentiment: Q4 results missed expectations — EPS of ($0.50) missed consensus by $0.07 and revenue of $1.14M missed estimates (~$3.25M). The miss raises near‑term financing and execution risk for a small‑cap biotech with limited revenue. MarketBeat Earnings
• Negative Sentiment: Curis reported an update indicating a pause in the emavusertib trial for certain indications (AML/MDS) — any trial pause increases clinical risk and could delay value realization from that program. Investors should watch for details on reasons for the pause and the path to restart. TipRanks
• Neutral Sentiment: Short‑interest notices in the data feed show anomalous/zero values and NaN changes — current published short interest figures do not present a reliable signal. Monitor official exchange short‑interest reports for clarity.

Wall Street Analyst Weigh In

CRIS has been the topic of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and set a $17.00 price target on shares of Curis in a report on Friday. Weiss Ratings restated a “sell (e+)” rating on shares of Curis in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $17.00.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.